Analyzing Phibro Animal Health (NASDAQ:PAHC) & GRI Bio (NASDAQ:GRI)

GRI Bio (NASDAQ:GRI) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for GRI Bio and Phibro Animal Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	0	0	2	0	3.00
Phibro Animal Health	2	2	0	0	1.50

GRI Bio currently has a consensus target price of $11.50, suggesting a potential upside of 1,719.62%. Phibro Animal Health has a consensus target price of $20.50, suggesting a potential downside of 6.01%. Given GRI Bio’s stronger consensus rating and higher probable upside, equities research analysts plainly believe GRI Bio is more favorable than Phibro Animal Health.

Insider and Institutional Ownership

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 0.1% of GRI Bio shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares GRI Bio and Phibro Animal Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$13.04 million	N/A	N/A
Phibro Animal Health	$1.02 billion	0.87	$2.42 million	$0.43	50.72

Phibro Animal Health has higher revenue and earnings than GRI Bio.

Profitability

This table compares GRI Bio and Phibro Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-289.05%	-165.01%
Phibro Animal Health	1.67%	21.59%	5.85%

Risk & Volatility

GRI Bio has a beta of -2.14, indicating that its stock price is 314% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Summary

Phibro Animal Health beats GRI Bio on 8 of the 11 factors compared between the two stocks.

About GRI Bio

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.